Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Leukaemia (chronic lymphocytic, relapsed) - rituximab: review decision - March 2014 information

Appendix B: GE decision paper - March 2014 (PDF 110 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: Review Proposal - January 2014 information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix A - provisional matrix of stakeholders (PDF 101 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 446 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - October 2012 information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: notice of appeal information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal announcement information

Appeal: UK Chronic Lymphocytic Leukaemia (CLL) Forum

Appeal received (PDF 28 KB)

Initial scrutiny letter (PDF 17 KB)

Response to initial scrutiny letter (PDF 93 KB)

Final scrutiny letter (PDF 8.7 KB)

Appraisal committee chair's response (PDF 81 KB)

Response to appraisal committee (PDF 247 KB)

Appeal: Joint: Royal College of Pathologists and British Society for Haematology

Appeal received (PDF 87 KB)

Initial scrutiny letter (PDF 19 KB)

Response to initial scrutiny letter (PDF 104 KB)

Final scrutiny letter (PDF 10 KB)

Appraisal committee response (PDF 55 KB)

Response to appraisal comittee (PDF 81 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal decision (PDF 35 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination (PDF 133 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: ERG response to error identified by manufacturer at consultation (PDF 16 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD

Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Royal College of Pathologists (PDF 62 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - RCN (PDF 23 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Cancer Research UK (PDF 55 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Roche (PDF 143 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD

Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Williams (PDF 15 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Barnard (PDF 23 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appraisal consultation document

Leukaemia (chronic lymphocytic, relapsed) - rituximab: appraisal consultation document information

Evaluation report

Pre-meeting briefing (PDF 157 KB)

Evidence Review Group report (PDF 3.01 MB)

Non-manufacturer submissions

UK CLL Forum (PDF 54 KB)

Royal College of Physicians (PDF 50 KB)

Royal College of Pathologists (PDF 54 KB)

Royal College of Nursing (PDF 7.6 KB)

NICE Submission - Rituximab for the treatment of relapsed/refractory Chronic Lymphocytic Leukaemia (PDF 5.19 MB)

Clarification stage

Manufacturer response to clarification - Roche response (PDF 1021 KB)

Manufacturer response to clarification - Response to request for clarification regarding PFS fit (PDF 28 KB)

NICE clarification - Parameters for curve fits (PDF 21 KB)

NICE clarification - letter (PDF 58 KB)

Expert written personal statements

Williams Durkin (PDF 51 KB)

Barnard (PDF 66 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (PDF 25 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (PDF 25 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the draft scope (PDF 129 KB)

Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the provisional matrix (PDF 19 KB)